Literature DB >> 8899048

Distribution of HLA-Dw2 in optic neuritis and multiple sclerosis indicates heterogeneity.

J Hillert1, T Käll, O Olerup, M Söderström.   

Abstract

UNLABELLED: The human leukocyte antigen (HLA) phenotype Dw2 is known to be increased in multiple sclerosis (MS), but only slightly in optic neuritis (ON).
MATERIAL AND METHODS: 127 consecutive patients with unilateral monosymptomatic ON were typed genomically for HLA-DR and -DQ genes.
RESULTS: The frequency of HLA-Dw2 among ON patients (47%) was found to be significantly higher than among 250 controls (30%) but significantly lower than in a group of 245 MS patients (60%), all of the same ethnic origin. At the group level, these figures can be calculated to indicate that 53% of the ON patients belong to the group of "MS-type ON" (95% confidence limits 25-78%). A compilation of published data on the frequency of the HLA-DR17(3), DQ2 haplotype, prompted by a slight increase in this material, revealed a significant association with this haplotype in ON, after compensation for the increase of Dw2.
CONCLUSION: ON differs from both MS and controls regarding HLA-Dw2. Thus, a substantial number of patients with ON may suffer from conditions not immuno-genetically related to MS, which might be designated as non-MS type ON. This condition may be more common in men and in young patients of both sexes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8899048     DOI: 10.1111/j.1600-0404.1996.tb07047.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  The relationship between HLA-DRB1 alleles and optic neuritis in Irish patients and the risk of developing multiple sclerosis.

Authors:  Ismail Tuwir; Ciaran Dunne; John Crowley; Tarik Saddik; Ray Murphy; Lorraine Cassidy
Journal:  Br J Ophthalmol       Date:  2007-10       Impact factor: 4.638

Review 2.  Immunopathogenic Background of Pars Planitis.

Authors:  Joanna Przeździecka-Dołyk; Agnieszka Węgrzyn; Anna Turno-Kręcicka; Marta Misiuk-Hojło
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-10-05       Impact factor: 4.291

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.